Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Dec;35(12):3445-3447.
doi: 10.1038/s41433-020-01325-9. Epub 2020 Nov 30.

Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy

Yonghui Xia  1 , Rui Hua  2   3
Affiliations
Comment

Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy

Yonghui Xia et al. Eye (Lond). 2021 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1. Choroidal neovascularization in a 47-year-old male patient with central serous chorioretinopathy.
A Fluorescein angiography showed macular leakage in his left eye (left image); indocyanine green angiography showed choroidal hyperpermeability in his left eye (right image). B En face optical coherence tomography angiography (OCTA) visualized choroidal neovascularization in the area of choroidal hyperpermeability (upper image); B-scan OCTA visualized the increased choriocapillary flow correspondingly (lower image). C OCTA demonstrated subretinal fluid, double layer sign of retinal pigment epithelium and increased thickness of choroidal vessels; the subretinal choroidal thickness was 525 μm.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Lotery A, Sivaprasad S, O’Connell A, Harris RA, Culliford L, Ellis L, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomized, double-blind, placebo-controlled trial. Lancet. 2020;395:294–303. doi: 10.1016/S0140-6736(19)32981-2. - DOI - PubMed
    1. Petkovsek DS, Cherfan DG, Conti FF, Hom GL, Ehlers JP, Babiuch AS, et al. Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience. Br J Ophthalmol. 2020;104:182–7. doi: 10.1136/bjophthalmol-2019-314047. - DOI - PubMed
    1. Fraenkel D, Suffo S, Langenbucher A, Seitz B, Din Abdin A. Eplerenone for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. 2020; 1120672120952648. Online ahead of print. - PubMed
    1. Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology. 2003;110:698–703. doi: 10.1016/S0161-6420(02)01975-9. - DOI - PubMed
    1. Zhao M, Célérier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Investig. 2012;122:2672–9. doi: 10.1172/JCI61427. - DOI - PMC - PubMed

MeSH terms

Substances